A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers | Zendy

Borja Mora-Peris | Zendy; Laura Else | Zendy; David Goldmeier | Zendy; Alison Mears | Zendy; Rosy Weston | Zendy; Graham Cooke | Zendy; Saye Khoo | Zendy; David Back | Zendy; Alan Winston | Zendy

Open Access

A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers

Author(s) -

Borja Mora-Peris,

Laura Else,

David Goldmeier,

Alison Mears,

Rosy Weston,

Graham Cooke,

Saye Khoo,

David Back,

Alan Winston

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv035

Subject(s) - boceprevir , pharmacokinetics , medicine , sildenafil , cmax , pharmacology , tolerability , adverse effect , hepatitis c virus , virology , ribavirin , virus

Boceprevir is a first-generation direct-acting antiviral licensed for the treatment of hepatitis C infection. Sildenafil is an oral therapy for erectile dysfunction. As boceprevir is a potent inhibitor of CYP3A4, potential pharmacokinetic interactions may occur when it is coadministered with sildenafil. The aim of this study was to assess the pharmacokinetic profile of sildenafil and boceprevir when dosed separately and together in healthy volunteers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research